In Reply We read with interest the response by Glazer et al regarding our study on the underuse of sentinel lymph node biopsy (SLNB) for high-risk cutaneous squamous cell carcinoma (cSCC)1 and noted several important inquiries and comments.
The results in our original article did not include numbers of patients so as to focus attention on the overall low percentage of high-risk cases managed with SLNB. As Glazer et al point out, this limits the reader’s ability to evaluate the power of the study and extrapolate the original data. During an 11-year period (2006-2017), 264 high-risk cSCCs were treated at our institution. Tumors were classified as high-risk if they met criteria as set forth by at least 1 of the 3 independent definitions that are most commonly used, specifically the American Joint Committee on Cancer (AJCC), the National Comprehensive Cancer Network (NCCN), and the group at Brigham and Women’s Hospital (BWH).1
Feinstein S, Sutton A, Wysong A. Potential Underuse of the Sentinel Lymph Node Biopsy for High-Risk Squamous Cell Carcinoma of the Skin—Reply. JAMA Dermatol. 2018;154(8):973. doi:10.1001/jamadermatol.2018.1824
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: